At the annual shareholders meeting on the 14th of October, Jarl Ulf Jungnelius was elected as Executive Director of the Biovica Board of Directors.
Ulf is a Board Certified Oncologist trained at the Karolinska University Institute/Hospital in Stockholm, Sweden and most recently held the position of Vice President CR&D Oncology at Celgene Inc. He comes with a wealth of over 20 years experience in pharmaceutical drug development and has previously held leading positions in CR&D at Pfizer, Eli Lilly and Takeda.
Ulf has held key roles in the clinical development of several successful oncology therapies like Abraxane®, Gemzar®, Alimta® and Revlimid®. In addition, he has played a key role in several multibillion-dollar acquisitions, such as Celgene’s acquisitions of Abraxis and Pharmion.
“I am excited to join Biovica and I see the potential in the DiviTum™ technology to address a major challenge within oncology treatments with poor treatment out-comes and short overall survival. DiviTum™ has potential to add value both for pharmaceutical companies developing new drugs, for payers and most importantly for cancer patients” says Ulf Jungnelius.
“Ulf’s unique competence and experience from both clinical and business development in the pharma industry is a great addition to the Board of Directors. Ulf joins Biovica in a very interesting phase as Biovica is entering several clinical trials with novel drugs from leading pharma companies.. This is an area where we want to make a contribution with our cell proliferation marker DiviTum to be able to select responders and evaluate therapy efficacy.”, states Anders Rylander, CEO